Canadian Market

IMV Stock Analysis & Ratings

TSE:IMV Stock Chart & Stats

Day’s RangeC$1.3 - C$1.36
52-Week RangeC$1.21 - C$3.01
Previous CloseC$1.35
Average Volume (3M)44.10K
Market CapC$107.77M
P/E Ratio-2.2
Next EarningsAug 10, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score7
EPS (TTM)-0.61



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.



What was IMV’s price range in the past 12 months?
IMV lowest stock price was C$1.21 and its highest was C$3.01 in the past 12 months.
    What is IMV’s market cap?
    IMV’s market cap is C$107.77M.
      What is IMV’s price target?
      The average price target for IMV is C$17.33. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is C$17.98 ,the lowest forecast is C$16.69. The average price target represents 1223.15% Increase from the current price of C$1.31.
        What do analysts say about IMV?
        IMV’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
          When is IMV’s upcoming earnings report date?
          IMV’s upcoming earnings report date is Aug 10, 2022 which is in 81 days.
            How were IMV’s earnings last quarter?
            IMV released its earnings results on May 13, 2022. The company reported -C$0.168 earnings per share for the quarter, beating the consensus estimate of -C$0.173 by C$0.005.
              Is IMV overvalued?
              According to Wall Street analysts IMV’s price is currently Undervalued.
                Does IMV pay dividends?
                IMV does not currently pay dividends.
                What is IMV’s EPS estimate?
                IMV’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does IMV have?
                IMV has 82,270,000 shares outstanding.
                  What happened to IMV’s price movement after its last earnings report?
                  IMV reported an EPS of -C$0.168 in its last earnings report, beating expectations of -C$0.173. Following the earnings report the stock price went up 0.787%.
                    Which hedge fund is a major shareholder of IMV?
                    Currently, no hedge funds are holding shares in TSE:IMV


                    IMV Stock Analysis

                    The IMV stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                    Learn more about TipRanks Smart Score

                    Company Description

                    IMV Inc.

                    IMV, Inc. is a clinical-stage biopharmaceutical company pioneering a new class of immunotherapy in Oncology. Its proprietary drug delivery platform (DPX) enables the programming of immune cells in vivo. The firm's candidate, DPX-Survivac, is a T cell-activating immunotherapy combining DPX with a specific tumor target: Survivin. DPX-Survivac is in clinical evaluation as a monotherapy in advanced ovarian cancer and in combination with Merck's Keytruda across multiple cancer indications. The company was founded by Warwick Kimmins and Brian E. Lowe on March 28, 2000 and is headquartered in Dartmouth, Canada.

                    Similar Stocks
                    Price & Change
                    Selecta Biosciences
                    Aquestive Therapeutics
                    Phasebio Pharmaceuticals
                    Hoth Therapeutics
                    Iterum Therapeutics

                    Popular Stocks

                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis